International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.
about
Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceInhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitorCan therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.Adding value to antiretroviral proficiency testingAnticonvulsant and antiretroviral interactions.Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratoriesPopulation pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations.
P2860
Q31135042-29AA8D36-50CD-44C4-9674-47653784BC4EQ33681426-6636FA25-6D3C-4EF4-8C71-C1F66ACED952Q33840412-FAC066A6-6688-4EA8-8D2E-23EF8CBAA64EQ33914723-95E44B10-BD19-4F37-B6D4-2D7F7BC1765BQ34114808-573C1BA4-1C25-41F5-B3E6-171E491D8960Q34976238-E9B977A7-60EC-4DF9-85DD-4A53C97A2E9FQ35670044-3625793A-7154-4EAB-8193-54328E3135D8Q35738878-1AD3D569-E0C8-4B93-9F96-5F757BF51146Q35917140-9FAE68DB-3A4A-48FD-ACA0-C828E84F8046Q36491759-0D44ED2D-FD59-4B12-9003-12430A89F6D2Q37193777-4D18E9F6-1645-47F5-A6AC-A38D1BAE4003Q37204267-B0D95748-ECEA-4C8E-B925-4707F473FD1AQ37835819-97AFC953-0A81-4782-92B8-B98D1F5BB2D5Q42052968-0D0D7CB5-8427-4B2B-838F-28424505D615Q46970955-300D8274-CB35-4C6F-8185-34CCF94BBD95Q53087320-584A5A22-86B5-4066-8888-450E67D22020
P2860
International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
International interlaboratory ...... ntiretroviral drugs in plasma.
@en
International interlaboratory ...... ntiretroviral drugs in plasma.
@nl
type
label
International interlaboratory ...... ntiretroviral drugs in plasma.
@en
International interlaboratory ...... ntiretroviral drugs in plasma.
@nl
prefLabel
International interlaboratory ...... ntiretroviral drugs in plasma.
@en
International interlaboratory ...... ntiretroviral drugs in plasma.
@nl
P2093
P2860
P1476
International interlaboratory ...... ntiretroviral drugs in plasma.
@en
P2093
Corrien P W G M Verweij-van Wissen
David M Burger
Eleonora W J van Ewijk-Beneken Kolmer
Eveline W Wuis
Peter P Koopmans
Rob E Aarnoutse
Yechiel A Hekster
P2860
P304
P356
10.1128/AAC.46.3.884-886.2002
P407
P577
2002-03-01T00:00:00Z